Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
4 Home Rec center Hardware Decisions for Little Spaces - 2Volkswagen in talks with defence firms on use of Germany plant: CEO
- 3Ski Resorts Universally: A Colder time of year Wonderland Guide
- 4The Best Games Crossroads in History
- 5'The Boys' Season 5 premiere: How to watch for less, what to know about the final series and more
- Four new luxury hotel openings in Italy you need to know about
- The 10 Most Significant Virtual Entertainment Missions
- Israeli strikes on Beirut, as Hezbollah and Iran attack Israel
- Grasping Various Kinds of Local misdemeanors
- Embrace the Outside: Exercises and Entertainment
- Strengthening through Wellness: Individual Preparation Achievement
- The last penny was pressed by the U.S. Mint in Philadelphia today. Could the nickel and dime be next?
- Golan resident convicted of spying for Iran after passing tank movement, missile-impact data
- New hybrid mpox strain discovered in UK after US reports local spread
